Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dalosirvat (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Biosplice Therapeutics; Samumed
- 06 Mar 2017 According to a Samumed media release, safety and efficacy results from this study presented during the 75th American Academy of Dermatology (AAD) Annual Meeting.
- 06 Mar 2017 Results published in a Samumed media release.
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.